TORONTO, Ontario – May 3, 2006: NeuroMedix Inc. (“NeuroMedix”) (TSXV: NMX) today announced that Dr. Mark Pearson, Chief Executive Officer of NeuroMedix, will present a company update at the BioFinance 2006 conference in Toronto. Dr. Pearson’s presentation is scheduled for May 4, 2006 at 11:30 a.m. EDT at the Toronto Marriott Eaton Centre.

NeuroMedix, a company focused on the development of therapeutic agents for the treatment of neuroinflammatory diseases, has commenced cGMP manufacture of its lead compound, Minozac, and expects to initiate pre-clinical toxicology studies, in preparation for a Phase I clinical trial, in the next few weeks. NeuroMedix’s clinical development plan is currently focused on Alzheimer’s disease, based on the efficacy of Minozac in preventing the release of neurotoxic cytokines from glia in a mouse model of Alzheimer’s and in blocking the loss of cognitive function in such mice. Nevertheless, in the effort to ensure that the full value of the aminopyridazine technology licensed from Northwestern University is fully realized, NeuroMedix is also investigating additional clinical indications where Minozac has potential to be effective through its action modulating neuroinflammation. These include neuropathic pain, traumatic brain injury and multiple sclerosis.

About NeuroMedix:

NeuroMedix is a biotechnology company focused on the development of therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease, multiple sclerosis and Parkinson’s disease. Our therapeutic drug candidates are based on research from a team of leading experts in the field of neuroinflammation at Northwestern University and have been demonstrated to reduce brain inflammation, to protect neuronal cells, and to prevent the loss of cognitive function in an Alzheimer’s disease animal model in mice. Based on these findings, NeuroMedix is pursuing the development of a lead compound for the prevention of Alzheimer's disease in humans. NeuroMedix’s shares are listed on the TSX Venture Exchange under the symbol “NMX”.

For further information visit www.neuromedixinc.com or contact:

Mark Pearson, PhD.
Chief Executive Officer
NeuroMedix Inc.
425-503-5156
mark@neuromedixinc.com

or

Catherine Auld, CA
Chief Financial Officer
NeuroMedix Inc.
416-673-8190
cathy@neuromedixinc.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may include but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.